[6-K] DR REDDYS LABORATORIES LTD Current Report (Foreign Issuer)
Rhea-AI Filing Summary
Dr. Reddy’s Laboratories has agreed to acquire the Indian trademarks and related assets of hormone replacement therapy brands Progynova® and Cyclo‑Progynova® from Mercury Pharma Group Limited for USD 32.15 million.
Progynova®, an estradiol valerate therapy, is described as the #1 brand in the estradiol represented pharmaceutical market in India and recorded sales of INR 100 crore as per IQVIA MAT December 2025. Cyclo‑Progynova® combines estradiol valerate and norgestrel for estrogen deficiency symptoms treatment.
The deal is not a related‑party transaction and is intended to strengthen Dr. Reddy’s gynecology portfolio in India and mark a strategic entry into the hormone replacement therapy segment.
Positive
- None.
Negative
- None.
Insights
Dr. Reddy’s buys leading Indian HRT brands to deepen its gynecology portfolio.
Dr. Reddy’s Laboratories is acquiring Indian rights to Progynova® and Cyclo‑Progynova® and related assets from Mercury Pharma Group Limited for
The transaction focuses on hormone replacement therapy for estrogen deficiency symptoms and postmenopausal osteoporosis prevention, broadening Dr. Reddy’s gynecology offering in India. Management frames the deal as a “spearhead” for expansion into the HRT segment, leveraging existing market access to extend these brands’ reach.
The acquisition is explicitly stated to be outside related‑party transactions, which simplifies governance considerations. Future disclosures in company filings may provide more detail on integration progress and how revenue from these brands contributes to the branded markets segment in India and emerging markets.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
February, 2026
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
Exhibit |
|
|
Number |
| Description of Exhibits |
|
|
|
99.1 | Intimation dated February 18, 2026 |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| DR. REDDY’S LABORATORIES LIMITED | ||
| (Registrant) | ||
|
|
|
|
Date: February 18, 2026 | By: | /s/ K Randhir Singh | |
|
| Name: | K Randhir Singh |
|
| Title: | Company Secretary |
| 3 |
Exhibit 99.1
| Dr. Reddy's Laboratories Ltd. |
8-2-337, Road No. 3, Banjara Hills | |
Hyderabad – 500 034, Telangana, India | |
| |
CIN: L85195TG1984PLC004507 | |
| |
Tel: + 91 40 4900 2900 | |
Fax: + 91 40 4900 2999 | |
Email: mail@drreddys.com | |
Web: www.drreddys.com |
February 18, 2026
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
Ref: | Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) |
This is to inform you that Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s”) has today, i.e., February 18, 2026, entered into a definitive agreement with Mercury Pharma Group Limited (“MPGL”), a UK-headquartered specialty pharmaceutical company, to acquire its trademarks, Progynova® and Cyclo-Progynova®, and related assets for India.
Further, the details as required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are as hereunder:
1
|
Name of the entity
|
Mercury Pharma Group Limited (“MPGL”)
|
2
|
Area of agreement
|
Dr. Reddy’s has acquired the trademarks, Progynova® and Cyclo-Progynova®, and related assets from MPGL for India
|
3
|
Domestic/ international
|
Domestic (India)
|
4
|
Share exchange ratio/ JV ratio
|
Not applicable
|
5
|
Scope of business operation of agreement
|
Through this deal, Dr. Reddy’s has acquired the trademarks, Progynova® and Cyclo-Progynova®, and related assets from MPGL for India
|
6
|
Details of consideration paid/
|
USD 32.15 million
|
7
|
Significant terms and conditions of agreement
|
Under the terms of the agreement, Dr. Reddy’s has acquired the trademarks, Progynova® and Cyclo-Progynova®, and related assets in India.
|
8
|
Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length
|
MPGL is not a related party to Dr. Reddy’s or any of its promoter/promoter group/ group companies. Therefore, this acquisition deal with MPGL does not fall within related party transactions.
Further, promoter/promoter group/ group companies do not have any interest in MPGL.
|
9
|
Size of the entity
|
Not applicable
|
10
|
Rationale and benefit expected
|
The acquisition strengthens Dr. Reddy’s Gynecology Portfolio in India through its foray into the Hormone Replacement Therapy segment.
|
A press release being issued in relation to the above matter is enclosed for reference.
This is for your information and records.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer & Head-CSR
Encl: As above
| CONTACT | |
DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | Aishwarya Sitharam aishwaryasitharam@drreddys.com | priya K PRIYAK@drreddys.com |
Dr. Reddy’s forays into Hormone Replacement Therapy segment with acquisition of Progynova® and Cyclo- Progynova® in India
Hyderabad India; February 18, 2026– Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), today announced that it has acquired the trademarks of specialty brands, Progynova® and Cyclo- Progynova® and related assets, for India from Mercury Pharma Group Limited, a UK-headquartered specialty pharmaceutical company.
Progynova® (estradiol valerate) is an oral hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms and for the prevention of postmenopausal osteoporosis 1. Cyclo-Progynova®2 (estradiol valerate and norgestrel) is a combined hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms, providing both estrogen and progestogen components 3. Progynova® is the #1 Brand in the Estradiol represented pharmaceutical market (RPM)4, with strong physician equity and brand recall in India. As per IQVIA MAT December 2025, the brand recorded sales of INR 100 cr. The acquisition strengthens Dr. Reddy’s gynaecology portfolio and marks a strategic entry into the hormone replacement therapy segment.
M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s, said: “The acquisition will serve as the spearhead of our expansion into the HRT segment, strengthening our existing gynaecology portfolio in India. With our established market access, we are uniquely positioned to extend the reach of the acquired assets and deliver greater impact. Furthermore, this acquisition brings a first-in-class treatment closer to patients, underscoring our commitment to innovation and patient care at the centre of everything we do.”
1 | Kuhl H. Pharmacology of estrogens and progestogens. Climacteric. 2005;8(Suppl 1):3-63 |
2 | Cyclo-Progynova® is currently not commercialised in India |
3 | Rossouw JE et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial.2002;288(3):321-333 |
4 | IQVIA MAT Dec’25 |
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2025. The company assumes no obligation to update any information contained herein.
Filing Exhibits & Attachments
1 documentPress Releases
